Q1 EPS Estimates for Nuvation Bio Decreased by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for Nuvation Bio in a research report issued on Monday, March 10th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.17) for the quarter, down from their prior estimate of ($0.15). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.71) EPS.

Several other equities analysts have also weighed in on NUVB. Jones Trading started coverage on Nuvation Bio in a report on Wednesday. They set a “buy” rating and a $10.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $5.00 price objective on shares of Nuvation Bio in a report on Monday, March 3rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective (up from $6.00) on shares of Nuvation Bio in a report on Tuesday, January 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $8.33.

Nuvation Bio Trading Down 1.1 %

Shares of NUVB opened at $2.22 on Wednesday. The stock has a 50 day moving average of $2.37 and a 200 day moving average of $2.57. Nuvation Bio has a 12 month low of $1.67 and a 12 month high of $4.16. The company has a market capitalization of $745.50 million, a price-to-earnings ratio of -1.02 and a beta of 1.47.

Hedge Funds Weigh In On Nuvation Bio

A number of large investors have recently made changes to their positions in the stock. Forum Financial Management LP bought a new position in shares of Nuvation Bio in the fourth quarter worth $29,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Nuvation Bio by 54.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 347,806 shares of the company’s stock worth $925,000 after acquiring an additional 122,187 shares during the period. Wexford Capital LP boosted its holdings in shares of Nuvation Bio by 45.2% in the fourth quarter. Wexford Capital LP now owns 946,219 shares of the company’s stock worth $2,517,000 after acquiring an additional 294,452 shares during the period. Two Sigma Investments LP boosted its holdings in shares of Nuvation Bio by 0.5% in the fourth quarter. Two Sigma Investments LP now owns 1,151,256 shares of the company’s stock worth $3,062,000 after acquiring an additional 5,925 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in shares of Nuvation Bio by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 51,060 shares of the company’s stock worth $136,000 after acquiring an additional 16,801 shares during the period. 61.67% of the stock is owned by institutional investors.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.